Dana McClintock, MD
Chief Medical Officer
Dana has 18+ years of biotech leadership experience, from food allergy to immunology and ophthalmology clinical development for anti-OX40L, XOLAIR® (omalizumab), Lucentis® (ranibizumab), and other pipeline programs. She supported IND-enabling activities, early and late phase clinical trials, and post-marketing commitments.
Prior to joining Navigator, Dana was CMO at Alladapt Immunotherapeutics, where she oversaw the lead immunotherapy program moving into the clinic and through positive Phase 1/2 results. Before that, Dana spent nearly 10 years at Genentech/Roche, holding leadership roles of increasing responsibility, including Global Head of Innovation for Immunology, Infectious Disease and Ophthalmology (I2O).
Dr. McClintock completed a Pulmonary & Critical Care Medicine Fellowship and an Internal Medicine Residency at UC San Francisco. She has an MD from the University of Virginia School of Medicine and a BA in Chemistry from Duke University.
